Novel regulation of mucosal innate defense by AMPK in Otitis Media

AMPK 对中耳炎粘膜先天防御的新调节

基本信息

  • 批准号:
    10229198
  • 负责人:
  • 金额:
    $ 45.98万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-04-07 至 2026-03-31
  • 项目状态:
    未结题

项目摘要

Mucin, a major protein component in mucus, plays a critical role in mucosal innate defense by providing a physical barrier and trapping pathogens for mucociliary clearance. If uncontrolled, excessive mucin production overwhelms mucociliary clearance and causes conductive hearing loss in otitis media (OM) and mucus obstruction in lung infections. Therefore, mucin production must be tightly regulated. However, the molecular mechanisms underlying the tight regulation of mucin remain largely unknown. Otitis media (OM) is the most common childhood bacterial infection and the leading cause of conductive hearing loss. It remains a major health problem and a substantial socioeconomic burden. S. pneumoniae, Sp, represents a major gram-positive bacterial pathogen for OM. Currently available Sp vaccines have a limited impact on OM. Moreover, inappropriate antibiotic use increased antibiotic-resistance. There is an urgent need for developing innovative non-antibiotic therapeutic agent for suppressing mucus overproduction. Our long-term goal is to elucidate the molecular mechanisms underlying OM pathogenesis and identify novel therapeutic targets. In contrast to the relatively well-known toll-like receptor (TLR)-dependent mechanisms by which Sp and pneumolysin (PLY – a key virulence factor produced by virtually all clinical Sp isolates) induce host mucosal immune response, the TLR-independent mechanisms including the key regulators remain largely unclear. Adenosine 5’-monophosphate-activated protein kinase α1 (AMPKα1) has emerged as a master regulator of host energy homeostasis. Its role in infectious diseases, in particular in the host mucosal innate defense response, e.g. mucus production, remains largely unclear. Our encouraging preliminary data suggest that Sp and PLY may up-regulate mucin MUC5AC and MUC5B via activation of AMPKα1 in a TLR2/4-independent manner in the middle ear and airway epithelial cells in vitro and in the mouse models of both acute and chronic OM. Interestingly, Sp and PLY may activate AMPKα1 by inducing novel non-traditional (protein degradation- independent) ubiquitination of AMPKα1 likely via downregulating a key deubiquitinase CYLD. Together, these exciting preliminary data have thus provided a solid foundation for us to hypothesize that [1] AMPKα1 acts as a key regulator for Sp-induced up-regulation of MUC5AC and MUC5B via TLR-independent signaling; [2] Activation of AMPKα1 by interplay between polyubiquitination and phosphorylation plays a critical role in Sp- induced up-regulation of MUC5AC and MUC5B (hypothesis). To test our hypothesis, we will pursue two specific aims to determine (Aim 1) the role of AMPKα1 in OM pathogenesis in both AOM and COM; and (Aim 2) how Sp activates AMPKα1. These studies will significantly advance our understanding of the key regulators including AMPK in TLR-independent host mucosal innate defense in bacterial infections and lead to the identification of novel therapeutic targets for controlling mucus overproduction. Our AMPK signaling studies may also help understand molecular mechanisms of other AMPK-related diseases (Significance and Impact).
黏液蛋白是黏液中的一种主要蛋白成分,在粘膜先天防御中起着至关重要的作用

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jian-Dong Li其他文献

Jian-Dong Li的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jian-Dong Li', 18)}}的其他基金

Novel regulation of mucosal innate defense by AMPK in Otitis Media
AMPK 对中耳炎粘膜先天防御的新调节
  • 批准号:
    10386875
  • 财政年份:
    2021
  • 资助金额:
    $ 45.98万
  • 项目类别:
Novel regulation of mucosal innate defense by AMPK in Otitis Media
AMPK 在中耳炎中对粘膜先天防御的新调节
  • 批准号:
    10599865
  • 财政年份:
    2021
  • 资助金额:
    $ 45.98万
  • 项目类别:
Pathogenesis of pneumococcal otitis media
肺炎球菌性中耳炎的发病机制
  • 批准号:
    9052165
  • 财政年份:
    2015
  • 资助金额:
    $ 45.98万
  • 项目类别:
Pathogenesis of pneumococcal otitis media
肺炎球菌性中耳炎的发病机制
  • 批准号:
    8884128
  • 财政年份:
    2015
  • 资助金额:
    $ 45.98万
  • 项目类别:
NF-kappaB Regulation by Human Pirin
人 Pirin 对 NF-kappaB 的调节
  • 批准号:
    8760952
  • 财政年份:
    2014
  • 资助金额:
    $ 45.98万
  • 项目类别:
NF-kappaB Regulation by Human Pirin
人 Pirin 对 NF-kappaB 的调节
  • 批准号:
    9057580
  • 财政年份:
    2014
  • 资助金额:
    $ 45.98万
  • 项目类别:
NF-kappaB Regulation by Human Pirin
人 Pirin 对 NF-kappaB 的调节
  • 批准号:
    9279172
  • 财政年份:
    2014
  • 资助金额:
    $ 45.98万
  • 项目类别:
NF-kappaB Regulation by Human Pirin
人 Pirin 对 NF-kappaB 的调节
  • 批准号:
    8919409
  • 财政年份:
    2014
  • 资助金额:
    $ 45.98万
  • 项目类别:
Combinational Regulation of Inflammation in Otitis Media
中耳炎炎症的联合调节
  • 批准号:
    7850281
  • 财政年份:
    2009
  • 资助金额:
    $ 45.98万
  • 项目类别:
Regulation of Host Response in S. pneumoniae Infections
肺炎链球菌感染中宿主反应的调节
  • 批准号:
    7588501
  • 财政年份:
    2009
  • 资助金额:
    $ 45.98万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 45.98万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 45.98万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 45.98万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 45.98万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 45.98万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 45.98万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 45.98万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 45.98万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 45.98万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 45.98万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了